Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)

Core Insights - Regeneron Pharmaceuticals is recognized for its strong R&D capabilities and has a promising pipeline of products expected to be released in the next 6 to 12 months [1] Company Overview - The discussion features key company representatives, including George D. Yancopoulos, who serves as Board Co-Chair, President, and Chief Scientific Officer, and Mark Hudson, Senior Director of Investor Relations [1][2] - The conference is part of the RBC Capital Markets Global Healthcare Conference, indicating the company's engagement with investors and analysts [1] Upcoming Developments - A significant upcoming catalyst for Regeneron is the Phase 3 data for Itepekimab related to Chronic Obstructive Pulmonary Disease (COPD), which is anticipated to provide insights based on previous data from asthma and COPD studies [5]